New drug navenibart aims to tame hereditary swelling attacks

NCT ID NCT05695248

Completed Disease control Sponsor: Astria Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early trial tested a new drug called navenibart in 29 people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. Participants received one or two doses of the drug to check its safety and how well it might reduce attacks. The study is a first step to see if navenibart could become a new treatment for HAE.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: navenibart (also called STAR-0215)
What this could lead to: If it works, this could lead to a new treatment option that reduces swelling attacks in people with hereditary angioedema.
What could go wrong: This is an early, small trial (29 people) testing the drug for the first time in this condition. It may not prove effective or safe enough for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angioedema hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY ANGIOEDEMA

Contacts and locations

Locations

AARA Research Center

Dallas, Texas, 75231, United States
Acuro Research, Inc.

Little Rock, Arkansas, 72205, United States
Addenbrooke's Hospital

Cambridge, CB2 0QQ, United Kingdom
Allergy & Asthma Clinic of Northwest Arkansas

Bentonville, Arkansas, 72712, United States
Allergy & Asthma Clinical Research

Walnut Creek, California, 94598, United States
Allervie Clinical Research

Birmingham, Alabama, 35209, United States
Charité Universitätsmedizin Berlin

Berlin, 12203, Germany
Diagnostical Consultative Center Convex Ltd.

Sofia, 1680, Bulgaria
Institute for Asthma and Allergy, PC

Chevy Chase, Maryland, 20815, United States
Institute of Clinical Immunology/Allergology, Faculty Hospital

Hradec Králové, 500 05, Czechia
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD.

Scottsdale, Arizona, 85251, United States
Optimed Research

Columbus, Ohio, 43235, United States
Ottawa Allergy Research Corporation

Ottawa, Ontario, K1H 1E4, Canada
Penn State Health Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States
Raffi Tachdjian MD, Inc

Santa Monica, California, 90404, United States
St. James's Hospital

Leeds, LS9 7TF, United Kingdom
UC San Diego US HAEA Angioedema Center

San Diego, California, 92122, United States
University of Alberta

Edmonton, Alberta, T6G 2R3, Canada
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.